Patents by Inventor Ebere F. IGBOKO

Ebere F. IGBOKO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors
    Patent number: 10336719
    Abstract: The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor. In addition, the invention relates to compositions containing the derivatives and processes for their preparation.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: July 2, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Weichun Chen, Ebere F Igboko, Xichen Lin, Hongfu Lu, Feng Ren, Paul Bryan Wren, Zhongmiao Xu, Ting Yang, Lindong Zhu
  • Novel Compounds
    Publication number: 20190010135
    Abstract: The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor. In addition, the invention relates to compositions containing the derivatives and processes for their preparation.
    Type: Application
    Filed: September 13, 2018
    Publication date: January 10, 2019
    Inventors: Weichun Chen, Ebere F. Igboko, Xichen Lin, Hongfu Lu, Feng Ren, Paul Bryan Wren, Zhongmiao Xu, Ting Yang, Lindong Zhu
  • 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors
    Patent number: 10106515
    Abstract: The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor In addition, the invention relates to compositions containing the derivatives and processes for their preparation.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: October 23, 2018
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Weichun Chen, Ebere F Igboko, Xichen Lin, Hongfu Lu, Feng Ren, Paul Bryan Wren, Zhongmiao Xu, Ting Yang, Lingdong Zhu
  • Use of CXCR2 Antagonists For The Prevention and/or Treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN)
    Publication number: 20170224679
    Abstract: The invention relates to the use of a CXCR2 antagonist for the prevention and/or treatment of chemotherapy induced peripheral neuropathy (CIPN).
    Type: Application
    Filed: July 27, 2015
    Publication date: August 10, 2017
    Inventors: Ebere F. IGBOKO, Paul Bryan WREN
  • 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS
    Publication number: 20170190681
    Abstract: The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor In addition, the invention relates to compositions containing the derivatives and processes for their preparation
    Type: Application
    Filed: May 27, 2015
    Publication date: July 6, 2017
    Applicant: Glaxosmithline Intellectual Property Development Limited
    Inventors: Weichun CHEN, Ebere F. IGBOKO, Xichen LIN, Hongfu LU, Feng REN, Paul Bryan WREN, Zhongmiao XU, Ting YANG, Lingdong ZHU